OSR Health, Inc. filed its Form 10-Q with the SEC on November 13, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $1,909,126 for the three months ended on that date.

Key Highlights

  • Net loss of $1,909,126 for the three months ended September 30, 2026, compared to a net loss of $3,194,874 in the same period of 2025, according to the filing.
  • Net sales of $524,793 for Q3 2026, down from $627,747 in Q3 2025, as reported in the condensed consolidated statements of operations.
  • Total assets of $185,773,224 as of September 30, 2026, up from $171,238,247 as of December 31, 2025, per the balance sheet.
  • Accumulated deficit of $42,564,395 as of September 30, 2026, compared to $37,169,881 as of December 31, 2025.
  • 35,258,692 shares of common stock issued and outstanding as of November 13, 2026, the filing disclosed.
  • Foreign currency translation gain of $17,211,165 in Q3 2026 resulted in total comprehensive income of $15,302,038 for the three-month period.
  • Goodwill increased to $33,120,723 as of September 30, 2026, from $24,949,806 as of December 31, 2025, reflecting business combination activity.

OSR Health Q3 2026: Operations, Balance Sheet, and Equity Changes

According to the filing, OSR Health, Inc. (NASDAQ:OSRH) reported net sales of $524,793 for the three months ended September 30, 2026, a decline from $627,747 in the comparable prior-year quarter. Cost of sales for the same period was $486,915, leaving a gross profit of $37,878. Selling, general, and administrative expenses of $3,101,562 resulted in an operating loss of $3,063,685 for the quarter. The company also disclosed an operating loss of $9,763,783 for the nine months ended September 30, 2026.

The filing reported a net loss of $1,909,126 for the three months ended September 30, 2026, of which $1,614,147 was attributable to OSR Health, Inc. and subsidiaries and $294,979 to non-controlling interests. Basic loss per ordinary share attributable to OSR Health, Inc. and subsidiaries was $(0.05) for the quarter and $(0.16) for the nine-month period. A foreign currency translation gain of $17,211,165 in Q3 2026 resulted in total comprehensive income of $15,302,038 for the three-month period, compared to total comprehensive loss of $5,452,663 in Q3 2025.

As of September 30, 2026, the company reported total assets of $185,773,224, including intangible assets, net, of $149,617,687 and goodwill of $33,120,723. Total liabilities stood at $45,562,368 and total stockholders' equity was $140,210,856. Cash and cash equivalents were $1,368,312 at quarter end, down from $1,700,273 at December 31, 2025. The filing noted that shares issued and outstanding increased to 35,118,692 as of September 30, 2026, from 26,597,769 as of December 31, 2025, reflecting share issuances including under an ELOC program and acquisition of non-controlling shares.

What Was Disclosed

OSR Health filed its quarterly report for the period ended September 30, 2026, disclosing a Q3 net loss of $1,909,126, net sales of $524,793, total assets of $185,773,224, and an accumulated deficit of $42,564,395, with a foreign currency translation gain substantially offsetting the period's operating losses.